

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of**  
**The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **January 28, 2013**

**WaferGen Bio-systems, Inc.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other jurisdiction  
of incorporation)

**000-53252**

(Commission  
File Number)

**90-0416683**

(IRS Employer  
Identification No.)

**7400 Paseo Padre Parkway, Fremont, CA**

(Address of principal executive offices)

**94555**

(Zip Code)

(Registrant's telephone number, including area code): **(510) 651-4450**

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**Item 7.01. Regulation FD Disclosure.**

On January 28, 2013, WaferGen Bio-systems, Inc. (the "Company") issued a press release announcing the results of a successful study of long non-coding RNA markers linked to prostate cancer in the lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center. A copy of the press release issued by the Company is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as we may specifically state in any such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release issued on January 28, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**WaferGen Bio-systems, Inc.**

Date: January 28, 2013

By: /s/ JOHN HARLAND  
John Harland  
Chief Financial Officer



EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release issued on January 28, 2013

---

January 28, 2013

**FOR IMMEDIATE RELEASE**

**WaferGen's MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center**

*Platform's Flexibility Key to a Successful Testing of Long Non-Coding RNA (lncRNA) Markers via High-Throughput Real-Time qPCR*

FREMONT, Calif., January 28, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the results of a successful study of lncRNA markers associated with prostate cancer in the lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center. The results can be viewed in white paper form at:

[http://www.wafergen.com/wp-content/uploads/2013/01/UM\\_lncRNA\\_TNf.pdf](http://www.wafergen.com/wp-content/uploads/2013/01/UM_lncRNA_TNf.pdf)

Under an existing agreement, WaferGen holds a license to this and other lncRNA-based research reagents developed by Dr. Chinnaiyan's lab.

Dr. Arul Chinnaiyan, the S.P. Hicks Professor of Pathology and Urology at University of Michigan and the lead author of the study stated: "The WaferGen SmartChip system is an ideal technology to validate the expression of novel lncRNAs nominated by RNA-seq in a highly parallel fashion. It allows us to test multiple primer sets for qPCR very efficiently and cost-effectively, because of the platform's flexibility. We were able to vary experiment formats in terms of number of analytes and samples that were driven by each experiment's design. Furthermore, we could change content rapidly by dispensing assays in our own lab using WaferGen's multi-sample nano-dispenser. We intend to validate a number of lncRNA panels for a variety of common solid tumors, and hope to translate the findings into clinical practice as proprietary diagnostics."

The latest marker validation study further underscores the now dual-role of WaferGen's SmartChip system in enhancing and augmenting experiments using Next-Gen sequencing (NGS). As recently announced, the system has shown promise upstream from NGS in target amplification, while downstream from NGS it can play a valuable role in target validation. This capability will enable a lab to prepare samples for targeted resequencing, and to confirm the NGS results via high-throughput nano-qPCR. Both applications leverage SmartChip's best-in-class flexibility, high levels of sensitivity and dynamic range without the need for pre-amplification, and a very low cost per reaction.

**About WaferGen and the SmartChip Real-Time PCR System**

WaferGen Bio-systems, Inc. is an innovative life science company that offers the SmartChip Real-Time PCR System—a next-generation genetic analysis platform for profiling and validating molecular biomarkers. It provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling as well as single nucleotide polymorphism (SNP) genotyping.

For additional information, please see <http://www.wafergen.com>

---

## **Forward Looking Statements**

This press release contains certain “forward-looking statements”. Such statements include statements relating to the expected benefits to the Company of using nano-qPCR technology for target enrichment sample preparation prior to targeted resequencing on Next-Gen platforms and other statements relating to future events that are not historical facts, including statements which may be preceded by the words “will,” “believes” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company. Actual results may differ materially from the expectations contained in the forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2011. Security holders are urged to read these documents free of charge on the SEC’s web site at [www.sec.gov](http://www.sec.gov). The Company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

## **WaferGen Contact:**

John Harland

[john.harland@wafergen.com](mailto:john.harland@wafergen.com)

510-780-2395